Tarceva and Hydramine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tarceva (erlotinib hydrochloride) and Hydramine (diphenhydramine hydrochloride). Common drug interactions include chest pain among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Tarceva and Hydramine. It is created by eHealthMe based on reports of 67 people who take the same drugs from the FDA, and is updated regularly.

What is Tarceva?

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in lung cancer. eHealthMe is studying from 31,036 Tarceva users. Check the latest studies of Tarceva.

What is Hydramine?

Hydramine has active ingredients of diphenhydramine hydrochloride. It is often used in insomnia. eHealthMe is studying from 114,900 Hydramine users. Check the latest studies of Hydramine.

On Aug, 09, 2026

67 people who take Tarceva and Hydramine together, and have interactions are studied.

Tarceva and Hydramine drug interactions.

What are the common drug interactions of Tarceva and Hydramine, by gender? *:

female:

Chest pain
Pain in extremity
Fall
Anaemia (lack of blood)
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Hypertension (high blood pressure)
Hypoaesthesia (reduced sense of touch or sensation)
Somnolence (a state of near-sleep, a strong desire for sleep)
Stomatitis (inflammation of mucous membrane of mouth)
Activities of daily living impaired

male:

Death
Diarrhoea
Erythema of eyelid (redness of the eyelid)
Malaise (a feeling of general discomfort or uneasiness)
Metastases to lung (cancer spreads to lung)
Onychalgia (nail biting)
Platelet count decreased
Neuropathy peripheral (surface nerve damage)
Peripheral coldness
Peripheral swelling

What are the common drug interactions of Tarceva and Hydramine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Activities of daily living impaired
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
Adrenal disorder
Anxiety
Atelectasis (partial or complete collapse of the lung)
Bone cyst
Bone loss
Cardiac failure congestive
Cerebral ischaemia (insufficient blood flow to the brain to meet metabolic demand)
Chest pain

50-59:

Blood pressure increased
Chest discomfort
Coagulopathy (blood's ability to clot is impaired)
Constipation
Decreased appetite
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Diarrhoea
Dry mouth
Dysuria (painful or difficult urination)

60+:

Vomiting
Diarrhoea
Dehydration (dryness resulting from the removal of water)
Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Oral pain
Blood pressure decreased
Decreased appetite
Dizziness
Dry eye (lack of adequate tears)
Epistaxis (bleed from the nose)

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 29 people, 43.28%
Pancreatic Carcinoma (pancreatic cancer): 6 people, 8.96%
Pain: 6 people, 8.96%
Osteopenia (a condition where bone mineral density is lower than normal): 6 people, 8.96%
Nausea (feeling of having an urge to vomit): 6 people, 8.96%
Anaemia (lack of blood): 5 people, 7.46%
Type 2 Diabetes: 4 people, 5.97%

* Approximation only. Some reports may have incomplete information.

Do you take Tarceva and Hydramine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously